



Swiss-S.Korean Joint Project

Development of AD Diagnostic Kit

March 10th, 2021
Webinar

 neurix



 PCL

Part I Project Goal & Plan

Part II Swiss – Korean Joint Project

01. History of Our Consortium
02. Challenges and Overcome
03. Outcome
04. Success Factors
05. Recommendations

Part III Further JV



Part I Project Goal & Plan

Control
MCI (Mild Cognitive Impairment)
AD (Alzheimer Disease)

iPSC lines




Screen of know compound
In MINIBRAIN 3D in vitro system

Blood & Exosome samples


Novel biomarker information

Novel biomarker
identification



AD relevant Biomarkers validation

Development of
AD diagnostic KIT



- Novel biomarker identification AD IVD kit development
- 3D minibrain model for AD Commercialization



Part II


Swiss – Korean Joint Project



History of Our Consortium

Challenges and Overcome

- Communication is delayed since the COVID-19 pandemic



COVID19 global cases (<https://coronavirus.jhu.edu/map.html>)

- Tried to keep in touch by email not to get lost where we were heading
- Arrange TC meeting and share opinions to overcome this difficulty

Challenges and Overcome

- **Built a strong rapport**
 - Before COVID-19 pandemic, we had 3 face-to-face meetings
 - Invited Swiss team researcher to Korea conference as a speaker



● Development of MCI/AD Diagnostic kit



Development of MCI/AD Diagnostic kit


Applied for a patent

출원번호통지서

출원 일자 2020.11.30
 특기 사항 심사청구(무) 공개신청(무)
 출원 번호 10-2020-0164819 (접수번호 1-1-2020-1293628-52)
 (DAS접근코드482C)
 출원인 명칭 피씨엘 (주)(1-2009-027998-2)
 대리인 성명 특허법인 한얼(9-2020-100061-3)
 발명자 성명 김소연 박건주
 발명의 명칭 액소중 유래 신규의 알츠하이머 진단용 바이오마커 및 이를 이용한 알츠하이머 진단방법

특 허 청 장

● Identified 3 MCI/AD biomarkers




● Sensitivity / Specificity > 80%





Success Factors

● Supplied Valuable AD Exosomes & Plasma Samples



● Respectable Colleagues in Discussion





Recommendations

- **Search for a Partner**

Please consider about **how** you can **combine** each one's **strengths** to create a **synergistic effect**.

- **Continuous cooperation**

In your own circumstances, even if **unexpected problems** arise, keep a **spirit of cooperation** to the end.

- **Advanced relationships like our JV**

Based on **this thankful joint project**, further **develop your partnership**.



Part III Further JV

Further JV

- Topics of the 'Further JV'



- We have an **advanced common goal** that is more valuable than the success of the joint project.



Elderly Patient Care

- 1) Diagnostics
- 2) Drug testing platform
- 3) Therapy
- 4) Medical devices to improve elderly patient's health

**Our 3 parties have negotiated the key term of JV
and are in the process of legal review of the detailed provisions.**

Thank you



Multiplex IVD Leader

Total Supplier of Multiplex In Vitro Diagnostics with
State-of-the art SG Cap™ Technology